Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05843305
Other study ID # BTP-661811
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date April 28, 2023
Est. completion date October 31, 2025

Study information

Verified date April 2023
Source Betta Pharmaceuticals Co., Ltd.
Contact Dingwei Ye, Ph.D
Phone 13701663571
Email fuscc2012@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This open-label Phase 1 study will evaluate the efficacy and safety of BPI-452080 in patients with Solid Tumors


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 87
Est. completion date October 31, 2025
Est. primary completion date March 25, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed locally advanced or metastatic solid tumor patients, who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists - Dose expansion phase: Arm1:has locally advanced or metastatic ccRCC and has progressed during treatment with at least one prior therapeutic regimen Arm2:Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Arm3:Other solid tumors - Adequate organ function - Evaluable lesion required for dose escalation phase and at least 1 measurable lesion required for dose expansion phase Exclusion Criteria: - Has received prior treatment with another HIF-2a inhibitor - Inadequate wash-out of prior therapies described per protocol, which may include anti-tumor therapies, tumor adjuvant drugs, organ or stem cell transplantation, moderate or strong CYP3A inhibitor or inducer, etc - Patients with major surgery within 4 weeks, severe or unstable systemic disease, unstable/symptomatic CNS metastasis, other malignant tumors, ILD, clinical significant cardiac disease, bleeding or embolic disease, active infectious disease, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results, in the opinion of the investigator or medical monitor - Pregnancy or lactation

Study Design


Intervention

Drug:
BPI-452080
Subjects will receive BPI-452080 until disease progression

Locations

Country Name City State
China West China Hospital of Sichuan University Chengdu
China Zhejiang Cancer Hospital Hangzhou
China Hunan Cancer Hospital Hunan
China Fudan University Shanghai Cancer Center Shanghai Shanghai
China Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan

Sponsors (1)

Lead Sponsor Collaborator
Betta Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary adverse events (AEs) Safety and tolerability will be assessed by monitoring frequency, duration and severity of adverse events Through the Phase I, approximately 24 months
Secondary Cmax Maximum observed concentration Through the Phase I, approximately 24 months
Secondary Tmax Time to reach maximum observed plasma concentration Through the Phase I, approximately 24 months
Secondary t1/2 Half-life time Through the Phase I, approximately 24 months
Secondary the objective response rate(ORR) The proportion of patients with complete response (CR) and partial response (PR) in all patients Through the Phase I, approximately 24 months
Secondary Progression free survival (PFS) The time from the date of randomization to disease progression (PD) or death, whichever occurs first Through the Phase I, approximately 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2